Tanzira Zaman

Title(s)HS Assistant Clinical Professor, Medicine
SchoolMedicine
ORCID ORCID Icon0000-0003-0286-4382 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Virginia, Charlottesville, VABA05/2008Biology, Bioethics
    New York Medical College, Valhalla, NYMD05/2013Medicine
    Georgetown Universtiy, Washington, DCResidency06/2016Internal Medicine
    University of Colorado, Denver, COFellowship06/2019Pulmonary & Critical Care Medicine

    Collapse Overview 
    Collapse Overview
    Dr. Tanzira Zaman is the Medical Director of the Interstitial Lung Disease program at Cedars-Sinai. She is also an Associate Program Director of the Cedars-Sinai Pulmonary & Critical Care Fellowship. Dr. Zaman's research focuses clinical trials in idiopathic pulmonary fibrosis. She is passionate about educating physicians-in-training and patients about interstitial lung disease.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Featured Content 
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Protein biomarkers of disease progression in patients with systemic sclerosis associated interstitial lung disease. Sci Rep. 2023 05 27; 13(1):8645. Cerro-Chiang G, Ayres M, Rivas A, Romero T, Parker SJ, Mastali M, Elashoff D, Chen P, Van Eyk JE, Wolters PJ, Boin F, Zaman T. PMID: 37244972; PMCID: PMC10224939.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    2. Cell-type-specific immune dysregulation in severely ill COVID-19 patients. Cell Rep. 2021 Mar 30; 34(13):108943. Yao C, Bora SA, Parimon T, Zaman T, Friedman OA, Palatinus JA, Surapaneni NS, Matusov YP, Chiang GC, Kassar AG, Patel N, Green CER, Aziz AW, Suri H, Suda J, Lopez AA, Martins GA, Stripp BR, Gharib SA, Goodridge HS, Chen P. PMID: 33789116; PMCID: PMC8009498.
      View in: PubMed   Mentions: 9     Fields:    
    3. Ventilatory Support in Patients with COVID-19. Adv Exp Med Biol. 2021; 1318:469-483. Leone PM, Siciliano M, Simonetti J, Lopez A, Zaman T, Varone F, Richeldi L. PMID: 33973195.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    4. Cell-Type-Specific Immune Dysregulation in Severely Ill COVID-19 Patients. Cell Rep. 2021 01 05; 34(1):108590. Yao C, Bora SA, Parimon T, Zaman T, Friedman OA, Palatinus JA, Surapaneni NS, Matusov YP, Cerro Chiang G, Kassar AG, Patel N, Green CER, Aziz AW, Suri H, Suda J, Lopez AA, Martins GA, Stripp BR, Gharib SA, Goodridge HS, Chen P. PMID: 33357411; PMCID: PMC7744012.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCells
    5. Cell type-specific immune dysregulation in severely ill COVID-19 patients. medRxiv. 2020 Jul 24. Yao C, Bora SA, Parimon T, Zaman T, Friedman OA, Palatinus JA, Surapaneni NS, Matusov YP, Chiang GC, Kassar AG, Patel N, Green CE, Aziz AW, Suri H, Suda J, Lopez AA, Martins GA, Stripp BR, Gharib SA, Goodridge HS, Chen P. PMID: 32743611; PMCID: PMC7386732.
      View in: PubMed   Mentions:
    6. Pre-existing traits associated with Covid-19 illness severity. PLoS One. 2020; 15(7):e0236240. Ebinger JE, Achamallah N, Ji H, Claggett BL, Sun N, Botting P, Nguyen TT, Luong E, Kim EH, Park E, Liu Y, Rosenberry R, Matusov Y, Zhao S, Pedraza I, Zaman T, Thompson M, Raedschelders K, Berg AH, Grein JD, Noble PW, Chugh SS, Bairey Merz CN, Marbán E, Van Eyk JE, Solomon SD, Albert CM, Chen P, Cheng S. PMID: 32702044; PMCID: PMC7377468.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCellsPHPublic Health
    7. Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. Basic Res Cardiol. 2020 05 12; 115(4):36. Singh S, Chakravarty T, Chen P, Akhmerov A, Falk J, Friedman O, Zaman T, Ebinger JE, Gheorghiu M, Marbán L, Marbán E, Makkar RR. PMID: 32399655; PMCID: PMC7214858.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsPHPublic Health
    8. Differences in Clinical Characteristics and Outcomes Between Men and Women With Idiopathic Pulmonary Fibrosis: A Multicenter Retrospective Cohort Study. Chest. 2020 07; 158(1):245-251. Zaman T, Moua T, Vittinghoff E, Ryu JH, Collard HR, Lee JS. PMID: 32084394; PMCID: PMC7339239.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    9. Risk factors for the development of idiopathic pulmonary fibrosis: A review. Curr Pulmonol Rep. 2018 Dec; 7(4):118-125. Zaman T, Lee JS. PMID: 31588408; PMCID: PMC6777743.
      View in: PubMed   Mentions: 23